The effect of timing on chemosensitization by clinical levels of SR-2508

Hirst, David; Horsman, Michael R.; Brown, J. Martin; Hazlehurst, J.L.

doi:10.1016/0360-3016(84)90519-4

Cited by 7 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the shark cartilage extract doses used in this study had did they influence the metastatic spread of this tumour to the lungs of the host animals. The SCCVII tumour model was selected for this study because it has been well documented, using both in vitro/in vivo excision and tumour growth delay assays, that primary tumours are responsive to conventional anti-cancer therapies such as radiation (19,20), chemotherapeutic drugs (17,18) and hyperthermia (21,22). Growth of this SCCVII tumour has also been shown to be reduced by the anti-angiogenic fumagillin analogue, TNP-470 (22).…”

Section: Resultsmentioning

confidence: 99%

The Effect of Shark Cartilage Extracts on the Growth and Metastatic Spread of the SCCVII Carcinoma

Horsman

Alsner²,

Overgaard³

1998

Acta Oncologica

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

The Effect of Shark Cartilage Extracts on the Growth and Metastatic Spread of the SCCVII Carcinoma

Horsman

Alsner²,

Overgaard³

1998

Acta Oncologica

View full text Add to dashboard Cite

“…For example, when 2"5 mmol/kg MISO doses have been utilized, tumor responses have generally been enhanced to a greater extent than normal tissue side effects [10,16,21]. In contrast, recent reports have demonstrated that at clinically achievable sensitizer doses, improved tumor responses could be attained in the absence of normal tissue toxicity or pharmacokinetic changes [5,6,11,16]. In contrast, recent reports have demonstrated that at clinically achievable sensitizer doses, improved tumor responses could be attained in the absence of normal tissue toxicity or pharmacokinetic changes [5,6,11,16].…”

Section: Discussionmentioning

confidence: 99%

Potentiation of CCNU activity by misonidazole in metastases

Siemann¹,

Alliet²

1987

Clin Exp Metast

View full text Add to dashboard Cite

The KHT sarcoma is a model system in which metastases can be studied in multiple organs without prior clonal selection. The present series of experiments were designed to evaluate and compare the extent of potentiation of chemotherapeutic agent activity by radiosensitizers when KHT sarcoma cells were grown in different anatomical sites. In these studies the effect of combining misonidazole (MISO) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) on KHT lung nodules and ovarian metastases was determined. Ovarian metastases were a consequence of the direct spread of tumor cells growing as lung nodules. Once established, KHT cells in the lungs and ovaries grew with a similar doubling time (1-2 days). Response of tumors at either site to chemotherapy in the presence or absence of a sensitizer was assessed using an in vivo to in vitro excision assay. MISO (1.0 mmol/kg) was administered simultaneously with a range of CCNU doses and survival of clonogenic tumor cells was measured 24 h after treatment. The results demonstrate that the addition of MISO to CCNU treatment potentiated the action of this chemotherapeutic agent at both tumor sites although greater cell kill enhancement occurred in the ovarian metastases. In the lung nodules, when combined with CCNU, a 1.0 mmol/kg dose of MISO was found to yield a dose modifying factor (DMF) of approximately 1.3. The same combination resulted in a DMF of approximately 1.8 in the ovarian metastases. This difference in DMF was not a result of an intrinsic difference in sensitivity to CCNU since cells grown at either site gave rise to the same dose response curve. Rather the difference in dose modification by MISO appears to be a consequence of the larger fraction of radiobiologically hypoxic cells in the ovarian tumors (approximately 50 per cent) than in the lung nodules (approximately 5 per cent) at the time of treatment. These findings suggest the use of drug-sensitizer combinations to treat disseminated disease and provide further evidence for the requirement of hypoxia in chemopotentiation by radiosensitizers.

show abstract

Non-chemotherapeutic agents that potentiate chemotherapy efficacy

Stewart

Evans

1989

Cancer Treatment Reviews

View full text Add to dashboard Cite

The effect of timing on chemosensitization by clinical levels of SR-2508

Cited by 7 publications

References 10 publications

The Effect of Shark Cartilage Extracts on the Growth and Metastatic Spread of the SCCVII Carcinoma

The Effect of Shark Cartilage Extracts on the Growth and Metastatic Spread of the SCCVII Carcinoma

Potentiation of CCNU activity by misonidazole in metastases

Non-chemotherapeutic agents that potentiate chemotherapy efficacy

Contact Info

Product

Resources

About